Evaluation
Improving Outcomes in Patients with Severe Familial Hypercholesterolemia - NO CREDIT
NON-PHYSICIAN INSTRUCTIONS
Thank you for participating. Please provide us with your educational activity evaluation.
What were your educational needs at the start of the activity?
Please indicate your response to the following questions:
No
Somewhat
Yes
Not Applicable
Were your educational needs met?
1
2
3
4
5
NA
After having participated, are you now able to:
Strongly Disagree
Not Sure
Strongly Agree
Describe the pathophysiology of severe familial hypercholesterolemia including the role of apolipoprotein B and lipoprotein(a) in lipid homeostasis.
1
2
3
4
5
Implement diagnostic strategies in pediatric and adult patients to appropriately risk stratify patients for genetic lipid disorders.
1
2
3
4
5
Utilize current treatment recommendations for improving the outcomes of patients with severe FH to reduce their elevated risk of CHD.
1
2
3
4
5
Track patient outcomes data to improve clinical research and decision-making that will improve identification of patients at risk for FH.
1
2
3
4
5
If
"Not Met"
, please explain for each objective.
Please rate the effectivness of the speakers
Low/Poor
High/Excellent
Not Applicable
Mary P. McGowan, MD
1
2
3
4
5
NA
Daniel J. Rader, MD
1
2
3
4
5
NA
James A. Underberg, MD
1
2
3
4
5
NA
Did the speakers encourage questions/discussion or other participation from the audience?
No
Somewhat
Yes
NA
If the answer is
no
, please explain:
Strongly Disagree
Not Sure
Strongly Agree
Was the content presented examined with sceintific rigor and evidence-based?
1
2
3
4
5
Was the scope, depth, and level of content appropriate?
1
2
3
4
5
Did the invitation and syllabus accurately convey the purpose and content?
1
2
3
4
5
Did the speaker provide a disclosure and disclose any off-label/investigational use of products discussed during their presentation?
1
2
3
4
5
Were the activities (e.g. speaker questions/discussion, case studies) that assessed learning appropriate?
1
2
3
4
5
Was the acitivity fair, balanced, and free of commercial bias?
1
2
3
4
5
If you answered 1, 2, or 3 in the above question, please describe the factors that contributed to the bias:
As a result of participating in this activity, what will you do differently to improve the care of your patients?
(Note: You will be reminded of this answer in a follow-up email survey)
What other topics would you like to see addressed in future NLA CME activities?
(choose all that apply)
Implementation of Treatment Guidelines
No
Yes
Clinical Trial Updates
No
Yes
Genetic disorders and testing
No
Yes
Advanced lipid testing
No
Yes
Emerging biomarkers of atherosclerosis
No
Yes
Atherosclerosis Imaging
No
Yes
Hypertriglyceridemia
No
Yes
Metabolic syndrome, diabetes, insulin resistance
No
Yes
Hypertension
No
Yes
Obesity management and weight loss
No
Yes
Acute Coranary Syndrome
No
Yes
HDL-C therapies
No
Yes
Aggresive LDL-C lowering through combination therapies
No
Yes
Special Populations: Women, Pediatrics, Ethnic Groups, HIV
No
Yes
Other:
Additional comments or suggestions for improvement?
Submit
